GLP-1 Nausea and Constipation in Women: A Practical Plan for the First Month

Nausea and constipation are the side effects most people on semaglutide or tirzepatide meet first, and the first month is when they peak. A plan made before your first dose makes them far easier to manage.

44% vs 16% In Wegovy's adult trials, nausea was reported by 44% of people on semaglutide versus 16% on placebo, and constipation by 24% versus 11%. Lilly's analysis of the tirzepatide trials found nausea and vomiting were reported more often by women.

Nausea and constipation are the most common side effects of GLP-1 weight-loss drugs, they are most likely in the first weeks and after each dose increase, and women tend to report them more than men. Most cases are mild to moderate and ease as your body adjusts. The things that help most are simple: eat smaller meals, stop at the first sign of fullness, go easy on greasy and very rich foods, drink fluids steadily through the day, and start a constipation plan before you need one. A few symptoms, including severe or persistent abdominal pain, repeated vomiting and signs of dehydration, need a call to your prescriber rather than home remedies.

What the labels and trials report

Side effectWegovy 2.4 mgPlaceboZepbound (5 / 10 / 15 mg)Placebo
Nausea44%16%25% / 29% / 28%8%
Diarrhea30%16%19% / 21% / 23%8%
Constipation24%11%17% / 14% / 11%5%
Vomiting24%6%8% / 11% / 13%2%

Figures from the Wegovy prescribing information and the Zepbound prescribing information. The trials were different, so don't compare the two drugs column against column; the point is how common these effects are relative to placebo.

On sex differences, a Lilly subgroup analysis of the SURMOUNT trials (Chao et al., 2024) reported that nausea and vomiting were consistently more frequent in females than males across studies. More in our breakdown of the SURMOUNT data by sex.

Why GLP-1s cause nausea and constipation

GLP-1 drugs slow how fast your stomach empties and act on appetite centers in the brain. That's a big part of why you feel full sooner and eat less. It's also why a normal-sized meal can suddenly feel like too much, why rich food can sit heavily, and why the gut can slow down enough to cause constipation. Eating and drinking less overall, including less fiber and fluid, adds to constipation.

Your first-month plan

This is a general framework for the first four weeks on a new GLP-1 or a new dose. It doesn't replace your prescriber's instructions, and it says nothing about dose: dosing for prescription peptides is set by the prescribing clinician.

Before your first dose

Week 1: learn your new fullness

Week 2: get ahead of constipation

Week 3: protein and steady eating

Week 4: review before any dose change

Quick reference: what tends to help

NauseaConstipation
Smaller, slower meals; stop at first fullnessFiber added gradually, with extra fluid
Plain, lower-fat foodsDaily walking or other movement
Steady sipping of fluids between mealsA regular time each day for a bathroom visit
Fresh air; avoiding strong food smellsPrescriber-approved OTC options if needed
Not lying down after eatingNot ignoring the urge to go

Red flags: when to call, and when to go now

GLP-1 labels list several serious warnings that can start with gut symptoms, including pancreatitis, gallbladder disease and kidney problems from dehydration. Call your prescriber promptly, or seek urgent care, if you have:

Women-specific notes

Does it get better?

For most people, yes. In SURMOUNT-1, gastrointestinal side effects were mostly mild to moderate and occurred mainly during dose escalation. If symptoms are still significant after your body has had time on a steady dose, that's a conversation about whether the dose, the schedule or the drug is right for you, not something you have to push through. Our semaglutide and tirzepatide profiles cover the broader side-effect picture.

Prescription Option (Telehealth)

If you're getting a GLP-1 through telehealth, make sure you can reach a clinician quickly when side effects come up, especially in the first month.

Oak offers GLP-1 care through telehealth. A licensed clinician reviews your history and decides whether a medication is appropriate. Any compounded medication is compounded and not FDA-approved.

Visit Oak

Sources

  1. Novo Nordisk. Wegovy (semaglutide) prescribing information, Adverse Reactions.
  2. Eli Lilly. Zepbound (tirzepatide) prescribing information, Adverse Reactions and oral contraceptive guidance.
  3. Chao A, et al. Body weight reduction associated with tirzepatide by sex: a subgroup analysis of the SURMOUNT clinical trials. Eli Lilly medical poster, 2024.
  4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.

Frequently Asked Questions

How common is nausea on Wegovy or Zepbound?
Very common. The Wegovy label reports nausea in 44% of people on semaglutide 2.4 mg versus 16% on placebo, and the Zepbound label reports 25% to 29% depending on dose versus 8% on placebo.
Do women get more nausea on GLP-1s?
A Lilly subgroup analysis of the SURMOUNT tirzepatide trials reported that nausea and vomiting were consistently more frequent in females than males across studies.
How long does GLP-1 nausea last?
It is usually worst when starting and after each dose increase and eases as the body adjusts. If symptoms remain significant on a steady dose, talk to your prescriber about the dose or schedule.
What helps constipation on semaglutide or tirzepatide?
Adding fiber gradually with extra fluid, daily movement such as walking, eating regularly rather than skipping meals, and using an over-the-counter option your prescriber has approved if diet changes are not enough.
When is GLP-1 stomach pain an emergency?
Seek prompt care for severe abdominal pain that will not go away, pain in the upper right abdomen with fever or yellowing skin, vomiting that stops you keeping fluids down, signs of dehydration, or blood in vomit or stool.

Related Reading

Medical Disclaimer: This article is for educational purposes only and is not medical advice. It is written by the FemPeptides editorial team from published research and is not reviewed by a clinician. Research-use-only peptides are not sold for human use. Talk to a licensed healthcare provider before starting, stopping or combining any treatment. Our editorial standards.
Affiliate Disclosure: FemPeptides earns commissions through some links on this page. This does not influence our evidence ratings or editorial content. Full disclosure →
Free Download

The Women's Peptide Guide

10 pages on peptides relevant to women's health and wellness goals, sourcing safely, and what to ask a provider.